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The consequence is poor performance in practice. However, one
does not need all genes on the array. One can proceed in two
steps, first reducing the number of genes to only a couple of
signature genes using conventional test statistics, and then
solving a low dimensional classification problem using standard
linear discriminant analysis. While this strategy works, the
resulting models have different properties on large-scale data,
than they would have in a low dimensional setting. The
large-scale setting imperatively requires a different kind of sta-
tistical thinking.
In this talk, I will point out the power and the limitations of
conventional statistical methodology in large scale profiling. I will
start with pointing out the specific statistical characteristics of
microarray-based diagnosis. To this end, I will discuss, how to
design a diagnostic microarray study, how to select marker genes,
how to determine an appropriate number of marker genes, how
to combine the expression levels of these genes to a diagnostic
signature, how to evaluate the performance of a signature, and
finally how to document a diagnostic signature for publication.
In all steps I will choose statistical concepts, which are as conven-
tional as possible for these tasks.
doi:10.1016/j.ejcsup.2006.04.019
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Conventional magnetic resonance imaging (MRI) in glioblastoma
models concentrates on high resolution imaging, the description
of pathophysiological changes by perfusion or diffusion weighted
imaging and the characterization of metabolites with magnetic
resonance spectroscopy.
With the advances in molecular biology and MRI there is rap-
idly growing interest in making radiological imaging techniques
more sensitive and specific for monitoring, diagnosing, and dif-
ferentiating biological processes.
The combination of information generated from molecular
genetics, the large number of animal models of human diseases
and new imaging techniques and contrast agents is the driving
force of developments in molecular imaging. Major goals of
molecular imaging by MRI are to image the presence of specific
molecules with targeted contrast agents to track cell migration,
follow changes in gene expression, and to develop strategies
enabling MRI to monitor other specific biological processes.
Encouraging results exist especially in the field of cell tracking
and monitoring gene expression using the signal reduction
caused by iron.
Problems encountered in the molecular imaging of glioblasto-
mas include the creation of a highly specific imaging agent,
access of the specific imaging agent to the molecular target (pas-
sage of the blood–brain barrier (BBB)) and an adequate imaging
quality with strong specific signal. Translation of in vitro concepts
to the in vivo application is often problematic. One major issue is
the size of the specific compound hindering the imaging agent to
pass the BBB or to pass even further to enter the cytoplasm. With
this problem being unsolved further progress needs to be done
before molecular imaging turns into a general imaging tool in ani-
mal models of glioblastoma.
doi:10.1016/j.ejcsup.2006.04.020
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Assessment of gene function following the completion of human
genome sequencing may be done using radionuclide imaging pro-
cedures. These procedures are needed for the evaluation of genet-
ically manipulated animals or new designed biomolecules which
requires a thorough understanding of physiology, biochemistry
and pharmacology. The experimental approaches will involve
many new technologies including in vivo imaging with SPECT
and PET. Nuclear medicine procedures may be applied for the
determination of gene function and regulation using established
and new tracers or using in vivo reporter genes such as genes
encoding enzymes, receptors, antigens or transporters. Visualiza-
tion of in vivo reporter gene expression can be done using radio-
labeled substrates, antibodies or ligands. Combinations of specific
promoters and in vivo reporter genes may deliver information
about the regulation of the corresponding genes. Furthermore,
protein–protein interactions and activation of signal transduction
pathways may be visualized non-invasively. The role of radiola-
beled antisense molecules for the analysis of mRNA content
has to be investigated. However, possible applications are thera-
peutic intervention using triplex oligonucleotides with therapeu-
tic isotopes which can be brought near to specific DNA sequences
to induce DNA strand breaks at selected loci. Imaging of labeled
siRNA’s makes sense if these are used for therapeutic purposes
in order to assess the delivery of these new drugs to their target
tissue.
In gene therapy based on the transfer and expression of sui-
cide genes usually genes coding for the non-mammalian
enzymes, the Herpes simplex virus thymidine kinase (HSVtk)
or the yeast and bacterial cytosine deaminase (CD), have been
used. After infection of the tumor with the recombinant virus,
a non-toxic prodrug is applied systemically, which is subse-
quently converted to a toxic metabolite by the recombinant gene
product. Employing a radiolabeled prodrug and scintigraphic
procedures it is possible to determine the functional activity of
the recombinant enzyme in vivo. This information can be used
to establish a therapeutic window of maximal gene expression
and consecutive drug administration. If the gene therapy
approach is based on the transduction of receptor genes, the
recombinant gene expression in tumor cells is monitored using
radiolabeled ligands. Transfer of transporter genes such as the
sodium iodide transporter may also permit the visualization of
transduction via accumulation of iodide or pertechnetate in
the targeted tissue.
Pharmacogenomics will identify new surrogate markers for
therapy monitoring which may represent potential new tracers
for imaging. Also drug distribution studies for new therapeutic
biomolecules are needed at least during preclinical stages of drug
development. New treatment modalities such as gene therapy
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with suicide genes will need procedures for therapy planning and
monitoring. Finally, new biomolecules will be developed by bioen-
gineering methods which may be used for isotope-based diagno-
sis and treatment of disease.
doi:10.1016/j.ejcsup.2006.04.021
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With an overall 5-year survival rate of approximately 4%, pan-
creatic ductal adenocarcinoma is one of the most aggressive
human malignancies. Studies that aimed at the understanding
of this exceptionally aggressive behavior discovered an increas-
ing number of genetic and epigenetic alterations such as dereg-
ulated growth factor receptor/ligand systems, oncogenes, tumor
suppressors, metastasis suppressors and related signal trans-
duction pathways. Alterations of these genes and their respec-
tive proteins may occur throughout pancreatic carcinogenesis
suggesting an adenoma-carcinoma model with an increasing
number of molecular and cellular alterations. The most com-
monly mutated oncogene in pancreatic cancer is K-ras which
induces cell proliferation via MAPK signaling. On the other
hand, mutations in tumor suppressors such as p53, p16 and
Smad4 also occur frequently. Besides, there are less common
mutations in the tumor suppressor genes STK11, APC, FHIT,
DCC, ARP, BRCA2, MKK4, TbR-I and TbR-II. Epigenetic alterations
in growth promoting signaling pathways of the EGF, IGF and FGF
family as well as autocrine or paracrine effects of their respec-
tive ligands have been shown to endow a growth advantage to
pancreatic cancer cells. Concomitantly, it was shown that the
important growth inhibitory pathway mediated by TGF-beta
family members and their intracellular signal transduction mol-
ecules is lost in pancreatic cancer. Resistance to apoptotic cell
death gives cancer cells a further growth advantage with down-
regulation of pro-apoptotic factors such as bak and bcl-2 or
upregulation of anti-apoptotic bcl-XL. Furthermore, aberrant
expression of genes influencing invasion and metastasis is
observed. Among those, heparanase, matrix metalloproteinases
and galectins have been shown to mainly influence invasion
while decreased expression of the metastasis suppressor KAI1
was associated with worse survival and an increased metastatic
potential.
Identified alterations of signal transduction pathways can be
used clinically as therapeutic targets, e.g. small-molecule tyrosine
kinase inhibitors and other approaches show encouraging results
in first clinical trials.
Thus, a translational research approach will be a promising
way to slow down tumor progression and improve survival and
quality of life of pancreatic cancer patients in the future.
doi:10.1016/j.ejcsup.2006.04.022
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In breast cancer, tumor biological markers are urgently needed
to individualize clinical decision making, particularly in order
to avoid overtreatment in the increasing number of patients
with small tumors. Urokinase-type plasminogen activator uPA
and its inhibitor PAI-1 are the first novel markers validated at
the highest level of evidence for their prognostic and predictive
impact by a multicenter therapy trial (Chemo N0) and a large
EORTC-RBG pooled analysis. Their greatest clinical use so far is
in node-negative (N0) breast cancer where the test can be used
to avoid adjuvant chemotherapy in patients with non-aggressive
disease. In addition, in intermediate-risk patients as defined by
the St. Gallen consensus, the test can be used to identify
patients who should receive chemotherapy because their tumor
has a more aggressive biology than classical pathological factors
would otherwise lead to believe. The NNBC3 therapy trial (AGO,
GBG, and EORTC PBG), which has already recruited almost 700
patients, compares risk assessment by uPA/PAI-1 to that by
established prognostic factors and evaluates optimization of
chemotherapy (FEC vs. FEC-DOC) in high-risk N0 patients. Other
promising markers include methylation markers such as PITX2
for identification of patients with good outcome under adjuvant
endocrine therapy, microarray signatures or multi-gene scores
for risk group stratification. In addition to NNBC3, other large
international therapy trials in N0 breast cancer using gene signa-
tures for risk group stratification will soon start recruitment.
The current and future challenge is to integrate the most prom-
ising tumor biological factors into advanced decision support
algorithms.
doi:10.1016/j.ejcsup.2006.04.023
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Intrinsic or acquired resistance to chemotherapy is responsible
for failure of current treatment regimens in breast cancer. For
instance, transcription factor YB-1 regulates expression of P-gly-
coprotein gene mdr1 which plays a major role in the development
of a multidrug-resistant tumor phenotype. High YB-1 protein
expression in tumor tissue and surrounding benign epithelial
cells is significantly associated with poor outcome in patients
who received postoperative chemotherapy, indicating clinical
drug resistance. Furthermore, in untreated patients, those with
low YB-1 protein expression are still free of disease, whereas
the 5-year relapse rate in those with elevated YB-1 is 30%.
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